Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | IDE | P14735 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 8/20 | 0.44 |
| ▸ | CA1 | P00915 | 8/20 | 0.44 |
| ▸ | CA2 | P00918 | 8/20 | 0.44 |
| ▸ | CA9 | Q16790 | 8/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | PLG | P00747 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL20495575 | 0.86 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL6734256 | 0.86 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL15067661 | 0.86 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1774374 | 0.84 | TDP1 (0.49) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1772652 | 0.84 | TDP1 (0.49) | TDP1MEN1ABL1LMNAPKM | |
| Palmitoyl Glycine SCHEMBL23295180 | 0.83 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31215417 | 0.81 | TDP1 (0.48) | TDP1MEN1ABL1LMNAPKM | |
| Lysine SCHEMBL9580131 | 0.81 | TDP1 (0.93) | TDP1MEN1ABL1LMNAPKM | |
| Palmitoyl Glycine SCHEMBL28600920 | 0.80 | FAAH (0.46) | TDP1MEN1KMT2A | |
| SCHEMBL29349497 | 0.79 | TDP1 (0.53) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201562-A1 | FORMULATIONS AND METHOD FOR TREATING BALDNESS | SEDERMA (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20060067905-A1 | Formulations and method for treating baldness | SEDERMA SAS (FR) | 2006-03-30 | — | — | US | disclosed |
| WO-2000058347-A1 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS CONTAINING TRIPEPTIDE N-BIOTINYL-GLY-HIS-LYS FOR THE PREVENTION, REDUCTION OR SUPPRESSION OF HAIR LOSS AND STIMULATION OF REGROWTH | SEDERMA (FR) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201562-A1 | FORMULATIONS AND METHOD FOR TREATING BALDNESS | CYP2R1, BTD, AGK | TDP1 4575/4885MEN1 4351/4885ABL1 4739/4885 |
| US-20060067905-A1 | Formulations and method for treating baldness | CYP2R1, BTD, AGK | TDP1 4575/4885MEN1 4351/4885ABL1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.